Corporate Offices
Technology
Dogwood has novel approaches to reduce pain signal transmissions and to treat reactivated herpes viruses.
Diseases
Dogwood is working on significant unmet medical needs in chemotherapeutic induced neuropathic pain (CINP), long COVID and fibromyalgia.
Clinical Trials
Dogwood will be evaluating the safety and effectiveness of Halneuron (HAL) vs placebo in people with established neuropathy due to their chemotherapy.
Breakthrough Therapeutics for Pain and Fatigue
Advancing Treatment
Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illness.
Pioneers in Treatment
Dogwood is also pioneering Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”).
Non-Opioid Pain Management
Dogwood’s Lead Candidate Halneuron® represents a breakthrough in painkiller technology:
-
No evidence of addiction, withdrawal symptoms, or euphoria
-
No build of up of tolerance overtime
-
Clinical evidence demonstrating long duration of pain relief with minimal, mild, and temporary side effects
-
Tested in over 700 people in clinical trials
CINP
CINP Chemotherapy treatments can cause peripheral neuropathy by damaging the nerves in the extremities.
Diseases
LONG COVID
Long COVID - Long COVID refers to the health problems that one may have after recovering from COVID-19.
FIBROMYALGIA
Fibromyalgia - Fibromyalgia (FM) is a widespread chronic pain disorder that lasts for 3 months or longer.